Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health
Recently created biotech Myovant has floated on the New York Stock Exchange to raise capital to progress its two lead candidate therapies; one for women's health conditions and another for prostate, and says Pfizer's sizable stake in the IPO reflects rising interest in these therapy areas.
You may also be interested in...
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.
Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.
Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.